Condition: Breast Cancer · Triple Negative Breast Cancer · Residual Cancer · Sponsor: Dana-Farber Cancer Institute
The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: * Sacituzumab govitecan * Atezolizumab
This description comes directly from the study's public registry record.
Elizabeth A Mittendorf, MD, PhD · 617-713-2294 · emittendorf@bwh.harvard.edu
Always discuss trial participation with your own doctor first.
| University of California San Francisco | San Francisco, California, United States | Recruiting |
| University of Chicago Medical Center | Chicago, Illinois, United States | Withdrawn |
| University of Chicago Comprehensive Cancer Center at Silver Cross Hospital | New Lenox, Illinois, United States | Withdrawn |
| University of Chicago Medical Center for Advanced Care Orland Park | Orland Park, Illinois, United States | Withdrawn |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| University of Pennsylvania-Abramson Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
| Vanderbilt-Ingram Cancer Center | Nashville, Tennessee, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04434040